MedTrace Logo

PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer

NCT02055690 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2021-05-17

No results posted yet for this study

Summary

The first part of this study is to find the recommended dosages of a combination of two drugs: pazopanib and fosbretabulin, which will be given to female patients with relapsed ovarian cancer.

The second part of the study involves comparing the recommended dose of pazopanib and fosbretabulin in combination against pazopanib alone in female patients with relapsed ovarian cancer to determine whether the combination is more beneficial that pazopanib on it's own.

Conditions

Interventions

DRUG

Pazopanib

Tyrosine Kinase Inhibitor

DRUG

Fosbretabulin

Vascular Disrupting Agent

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Mateon Therapeutics

    collaborator INDUSTRY

  • East and North Hertfordshire NHS Trust

    collaborator OTHER_GOV

  • The Christie NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Gordon Jayson · The Christie National Health Service (NHS) Foundation Trust

  • Gordon Rustin · East and North Herts NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2017-11-24
Completion
2017-11-24

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02055690 on ClinicalTrials.gov